Loading clinical trials...
Loading clinical trials...
A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
Age
40 - No limit years
Sex
ALL
Healthy Volunteers
No
Palmetto Medical Research Associates L.L.C.
Easley, South Carolina, United States
Start Date
September 1, 2015
Primary Completion Date
August 1, 2016
Completion Date
September 1, 2016
Last Updated
February 24, 2022
611
ACTUAL participants
TD-4208
DRUG
Placebo
DRUG
Lead Sponsor
Mylan Inc.
Collaborators
NCT07477600
NCT07382258
NCT07195838
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions